Poolbeg expands POLB 001 into oncology
Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is…
January 17, 2023 - 3 minutes
Poolbeg Pharma
Poolbeg identifies new potential drug candidates for RSV infections
Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial…
December 21, 2022 - 3 minutes
Poolbeg influenza trial successfully completed
Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial…
December 13, 2022 - 3 minutes
Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform
EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.4 million) in non-dilutive…
November 16, 2022 - 3 minutes
AI program yields multiple novel RSV drug targets
Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with…
November 8, 2022 - 3 minutes
Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments
Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for…
October 4, 2022 - 2 minutes
